scorecardresearch
Add as a preferred source on Google
Sunday, December 21, 2025
TopicBharat Biotech

Topic: Bharat Biotech

Covid vaccine patents can be waived without hurting firms like Bharat Biotech. Here’s how

It is time countries acted with a humanitarian approach at WTO and relaxed IPR provisions for Covid-19 vaccines. And it can be done without disincentivising R&D efforts.

9 states tell SC they’re unlikely to get enough Covid vaccines stock for 18+ group by May-end

In affidavits to SC, 9 states have said SII & Bharat Biotech have either expressed inability to supply the stock by May-end or said there will be staggered delivery over the next 2-3 months.

Disheartening to see some states complaining about Covaxin supply intentions — Bharat Biotech

In a tweet Wednesday, Bharat Biotech Joint Managing Director Suchitra Ella said the company has already dispatched Covaxin lots to 18 states on 10 May.

Bharat Biotech refuses to supply Covaxin to Delhi citing govt directives, alleges Sisodia

Delhi Deputy CM Manish Sisodia said Covaxin manufacturer in a letter referred to instructions from govt officials and it means that central govt is controlling the vaccine supply.

Modi govt expert panel recommends Covaxin for phase 2/3 clinical trials on 2-18-yr-olds

Covaxin, indigenously developed by Bharat Biotech in collaboration with the Indian Council of Medical Research, is being used on adults in India's ongoing Covid vaccination drive.

Still playing the book-vaccine-slot game on CoWin? That’s because there’s a shortage of doses

Modi govt Friday said it had told states to prioritise second dose of Covid vaccines over first dose in a 70:30 ratio, in what may be its first admission about shortage of vaccines.

Bharat Biotech reduces Covaxin price for state govts to Rs 400 per dose

The move to cut the price from Rs 600 per dose follows widespread criticism of Bharat Biotech's pricing policy as it sold Covaxin to the central government at Rs 150 per dose.

Modi govt asks Serum Institute, Bharat Biotech to lower prices of Covid vaccines

The move comes after many states objected to different pricing of the vaccines, with Delhi CM Arvind Kejriwal saying this is not time for profiteering.

Bharat Biotech scales up Covaxin manufacturing capacity to 700 million doses a year

The company had 200 million doses capacity when it started producing Covaxin in the beginning, say sources.

Modi govt approves Rs 4,500-cr advance payment to help vaccine makers ramp up production

SII will supply 200 million doses and Bharat Biotech is to supply another 90 million doses to the government by July at a pre-agreed rate of Rs 150 per dose.

On Camera

Henry George’s Single Tax offers a democratic alternative to communist remedies: DM Kulkarni

The immediate benefit of Single Tax would be to reduce the sale prices of land to nominal ones. Landowners would no longer find it profitable to keep idle lands, wrote DM Kulkarni in 1960.

China is taking India to WTO over subsidies, again. Here’s what it’s arguing before trade body

Dispute will now move to consultative process, which allows the two sides to come to an amicable agreement within 60 days.

Israel has ‘realised who its real friend is’, eyes defence expansion in India amid arms curbs by others

It is argued that India-Israel ties are moving from buyer–seller dynamic to one focused on joint development & manufacturing partnership, a shift 'more durable' than traditional arms sales.

Dhurandhar shows hard cinema is soft power and Pakistan is unapologetically the target

If Pathaan gave both conservatives and liberals room to hide, Dhurandhar extends no such courtesy. Aditya Dhar ripped open that tent of hypocrisy and turned the knife.